New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology

REFERENCES

• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Arceci RJ, eds. Molecularly Targeted Therapy for Childhood Cancer. New York: Springer; 2010.
   Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350: 2129–2139.
   PubMed Web of Science ®Google Scholar
• Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011;11:247–256.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Lipton A, Hayes DF, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–2671.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Hattinger CM, Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005;41:1349–1361.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Stewart CF, Kocak M, A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13:290–297.
   Google Scholar
• Jakacki RI, Hamilton M, Gilbertson RJ, Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008;26:4921–4927.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–543.
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu MC, Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993–1999.
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Linardou H, Kosmidis P, EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol. 2011;22:545–552.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert SY, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134.
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338.
   PubMed Web of Science ®Google Scholar
• Janeway KA, Albritton KH, Van Den Abbeele AD, Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009;52:767–771.
   PubMed Web of Science ®Google Scholar
• Lokker NA, Sullivan CM, Hollenbach SJ, Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62:3729–3735.
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR, Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12: 4899–4907.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Blaney SM, Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145–160.
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Woods WG, Stirewalt DL, Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117:3294–3301.
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Kalebic T, Blakesley V, The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272:30822–30827.
   PubMed Web of Science ®Google Scholar
• Juergens H, Daw NC, Geoerger B, Preliminary efficacy of the anti-insulin like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011; in press.
   Google Scholar
• Passoni L, Longo L, Collini P, Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69:7338–7346.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Millot F, Guilhot J, Nelken B, Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20:187–192.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27:5175–5181.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Blaney SM, Strauss LC, Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011;29:839–844.
   PubMed Web of Science ®Google Scholar
• Vitali R, Mancini C, Cesi V, Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int J Cancer. 2009;125:2547–2555.
   PubMed Web of Science ®Google Scholar
• Shor AC, Keschman EA, Lee FY, Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007;67:2800–2808.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Dworzak M, Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol. 2010;149:399–409.
   PubMedGoogle Scholar
• Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985;313:404–406.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007–1013.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Luksch R, Lo Piccolo MS, Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003;9:2032–2039.
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Loh ML, Jayaprakash N, Phase II window study of R115777 (Zarnesta) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group study. Blood. 2005;106:727a.
   Web of Science ®Google Scholar
• Guha A, Feldkamp MM, Lau N, Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15:2755–2765.
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Banerjee A, Poussaint TY, Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13:298–306.
   PubMed Web of Science ®Google Scholar
• Garber K. Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst. 2001;93:1519.
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357–361.
   PubMed Web of Science ®Google Scholar
• Quek R, Wang Q, Morgan JA, Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17:871–879.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• Real PJ, Tosello V, Palomero T, Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15:50–58.
   PubMed Web of Science ®Google Scholar
• Deangelo DJ, Stone RM, Silverman LB, A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006; ASCO Annual Meeting Proceedings 24(18S).
   Google Scholar
• Bonapace L, Bornhauser BC, Schmitz M, Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120:1310–1323.
   PubMed Web of Science ®Google Scholar
• Romer JT, Kimura H, Magdaleno S, Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell. 2004;6:229–240.
   PubMed Web of Science ®Google Scholar
• Major MB, Camp ND, Berndt JD, Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007;316:1043–1046.
   PubMed Web of Science ®Google Scholar
• Erkizan HV, Kong Y, Merchant M, A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15:750–756.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–39.
   PubMed Web of Science ®Google Scholar
• Furlan I, Batz C, Flotho C, Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113:2867–2868.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Meister S, Schubert U, Neubert K, Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783–1792.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55:254–259.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Meinhardt A, Burkhardt B, Zimmermann M, Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28:3115–3121.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–179.
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15:6217–6224.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Zimmerman M, Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148:768–776.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Zugmaier G, Henze G, Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25:181–184.
   PubMed Web of Science ®Google Scholar
• Liersch R, Berdel WE, Kessler T. Angiogenesis Inhibiton. Berlin: Springer; 2010.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142–148.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008;26:399–405.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2011 [Epub ahead of print].
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Kuhn J, Lamborn KR, Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2011 [Epub ahead of print].
   Google Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26:919–924.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Mitchell EP, Piperdi B, Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–1357.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, von Pawel J, Vynnychenko I, First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011;12:30–37.
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28:949–954.
   PubMed Web of Science ®Google Scholar